|
Market Cap (24-Jun) $1,569,461,888 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (26-May) 7,938,725 (6.28%) (46th) |
|
52w High $22.99 |
52w Low $11.00 |
P/E 49.75 |
EPS 0.23 |
NEU released this announcement to the ASX on 29 October 2020, 9:50. The announcement is marked as price sensitive, and is 9 page(s) in length and 265.24kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.027% short sold according to ASIC data. It was ranked the 483rd most shorted stock on the ASX. It is now ranked as the 46th most shorted stock on the ASX with 6.280% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Neuren receives US$40m milestone payment | 7 June 2023, 15:19 |
| Neuren presenting at Jefferies Global Healthcare Conference | 5 June 2023, 16:32 |
| Results of Meeting | 30 May 2023, 16:36 |
| Quarterly report and cash flow statement for Q3 2020 | 29 October 2020, 9:50 |
| There has been no announcements made to the ASX since this one. |
You must be logged in to post a reply.
Neuren Pharmaceuticals 